PDF(Pubmed)
Abstract：
UNASSIGNED: With the development of the novel coronavirus disease 2019 (COVID-19), China implemented measures in an attempt to control the infection rate. We conducted a single-center, cross-sectional study to ascertain the impact of the COVID-19 pandemic on the equitable availability of medical resources for children diagnosed with malignant solid tumors in China.
UNASSIGNED: Data on the demographics, clinical characteristics, and medical expenses of 876 patients diagnosed with neuroblastoma, rhabdomyosarcoma (RMS), Wilms tumor, hepatoblastoma (HB), Ewing sarcoma (ES), and central nervous system (CNS) tumors from 2019 to 2021, during the COVID-19 pandemic, were retrospectively collected from the National Center for Children\'s Health. The Pearson χ2 test and Mann-Whitney test were performed to analyze the differences among variables.
UNASSIGNED: Except for the regional origin of children with tumors during the epidemic, no significant differences were found in the demographic or clinical characteristics of patients at initial diagnosis. The number of patients from northern China and northeastern China who attended Beijing Children\'s Hospital (BCH) increased after the outbreak of COVID-19 (P=0.001). There was no significant alteration observed in the frequency of hospitalizations per individual per annum (P=0.641) or the mean expense incurred per individual per hospitalization (P=0.361). In addition, the medical insurance coverage rate of real-time settlement increased year by year.
UNASSIGNED: After the COVID-19 outbreak, the origin of patients with solid tumor who visited BCH was concentrated in the northern region of China. COVID-19 had no impact on the other demographic factors, clinical characteristics, or economic burden of patients with pediatric malignant solid tumors.
UNASSIGNED: Data on the demographics, clinical characteristics, and medical expenses of 876 patients diagnosed with neuroblastoma, rhabdomyosarcoma (RMS), Wilms tumor, hepatoblastoma (HB), Ewing sarcoma (ES), and central nervous system (CNS) tumors from 2019 to 2021, during the COVID-19 pandemic, were retrospectively collected from the National Center for Children\'s Health. The Pearson χ2 test and Mann-Whitney test were performed to analyze the differences among variables.
UNASSIGNED: Except for the regional origin of children with tumors during the epidemic, no significant differences were found in the demographic or clinical characteristics of patients at initial diagnosis. The number of patients from northern China and northeastern China who attended Beijing Children\'s Hospital (BCH) increased after the outbreak of COVID-19 (P=0.001). There was no significant alteration observed in the frequency of hospitalizations per individual per annum (P=0.641) or the mean expense incurred per individual per hospitalization (P=0.361). In addition, the medical insurance coverage rate of real-time settlement increased year by year.
UNASSIGNED: After the COVID-19 outbreak, the origin of patients with solid tumor who visited BCH was concentrated in the northern region of China. COVID-19 had no impact on the other demographic factors, clinical characteristics, or economic burden of patients with pediatric malignant solid tumors.
摘要：
■随着2019年新型冠状病毒病（COVID-19）的发展，中国采取措施试图控制感染率。我们进行了一个单中心，横断面研究，以确定COVID-19大流行对中国诊断为恶性实体瘤的儿童医疗资源的公平可用性的影响。
■人口统计数据，临床特征,876例神经母细胞瘤患者的医疗费用，横纹肌肉瘤(RMS),肾母细胞瘤，肝母细胞瘤（HB），尤因肉瘤(ES),和中枢神经系统（CNS）肿瘤，从2019年到2021年，在COVID-19大流行期间，从国家儿童健康中心回顾性收集。采用Pearsonχ2检验和Mann-Whitney检验分析各变量之间的差异。
■除了流行期间肿瘤儿童的区域起源，初次诊断时患者的人口统计学或临床特征无显著差异.在COVID-19爆发后,中国北方和中国东北到北京儿童医院(BCH)就诊的患者数量增加(P=0.001)。每个人每年的住院频率（P=0.641）或每个人每次住院的平均费用（P=0.361）没有显着变化。此外,医保实时结算覆盖率逐年提高。
■COVID-19爆发后，参观BCH的实体瘤患者的起源集中在中国北部地区。COVID-19对其他人口因素没有影响，临床特征,或儿童恶性实体瘤患者的经济负担。
■人口统计数据，临床特征,876例神经母细胞瘤患者的医疗费用，横纹肌肉瘤(RMS),肾母细胞瘤，肝母细胞瘤（HB），尤因肉瘤(ES),和中枢神经系统（CNS）肿瘤，从2019年到2021年，在COVID-19大流行期间，从国家儿童健康中心回顾性收集。采用Pearsonχ2检验和Mann-Whitney检验分析各变量之间的差异。
■除了流行期间肿瘤儿童的区域起源，初次诊断时患者的人口统计学或临床特征无显著差异.在COVID-19爆发后,中国北方和中国东北到北京儿童医院(BCH)就诊的患者数量增加(P=0.001)。每个人每年的住院频率（P=0.641）或每个人每次住院的平均费用（P=0.361）没有显着变化。此外,医保实时结算覆盖率逐年提高。
■COVID-19爆发后，参观BCH的实体瘤患者的起源集中在中国北部地区。COVID-19对其他人口因素没有影响，临床特征,或儿童恶性实体瘤患者的经济负担。
